Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Warfarin has been the mainstay of anticoagulation therapy for the past several decades, but difficulties associated with its use and the clinical management of patients have prompted the development of novel oral anticoagulants (NOACs). The anticoagulant effects of these new agents allow for their use across multiple indications such as venous thromboembolism (VTE), atrial fibrillation (AF), and acute coronary syndrome (ACS). In China, approvals of several NOACs such as Pradaxa (Boehringer Ingelheim’s dabigatran etexilate), Eliquis (Bristol-Myers Squibb/Pfizer’s apixaban), and Xarelto (Bayer/Janssen’s rivaroxaban) in recent years have increased the availability of these drugs in the country and broadened treatment options for physicians and patients. The inclusion of Xarelto into the National Reimbursement Drug List (NRDL) as a type B drug may be the country’s first sign of readiness to adopt other NOACs into the national health insurance coverage.
Decision Resources Group’s Emerging Markets Physician & Payer Forum report “Novel Oral Anticoagulants in China: Physician and Payer Perspectives on the Evolving Treatment of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome” explores the prescribing patterns of current anticoagulant therapies, the impact of increased access and availability of NOACs, and key national and regional market access factors that will shape the use of novel drugs for VTE, AF, and ACS treatment in China in the next two to three years. It draws on insights from 50 surveyed cardiologists and from interviews with 3 interviewed payers in China, all of whom have influence at a national or regional level. Interviewed payers include the following:
- NRDL panel member, Beijing: Hospital chief physician, director of cardiology, professor of clinical integrative medicine.
- CFDA consultant, Beijing: Hospital chief physician, deputy director of clinical pharmacology center, member of Beijing municipal committee of clinical pharmacology, Beijing health insurance accreditation expert.
- NRDL panel member, Hunan: Hospital professor, member of Medical Society of Cardiology Professional Committee, fellow of American College of Cardiology.